This means that kangxinuo biological return to A-share listing is a step further.
Investors in the Hong Kong market voted with their feet. On the morning of the 23rd, Hong Kong stock market kangxinuo biological-b rose 5% in the opening, and soon broke the position and fell. Some investors have said that profitability is the key. No matter how much good news the new crown vaccine has, it cant be commercialized. Whats the use?
As of the press release, conconor bio-b has fallen by more than 3% and its market value has shrunk to about HK $48 billion, with an additional issuance of over HK $4 billion compared with the opening of this morning.
Raise 1 billion for R & D and production of new coronal vaccine
According to the prospectus of kangxinuo biological Co., Ltd., as of March 31, 2020, the first quarter of kangxinuo biological Co., Ltd. has realized a revenue of 4.03 million yuan, a year-on-year increase of 605.1%, and the net loss attributable to the shareholders of the parent company was 23.103 million yuan, with a year-on-year decrease of 48.94%. As the vaccine products have not yet been commercialized, consinor has not achieved profit in the reporting period. The fifth set of listing standards is adopted in the IPO of the science and technology innovation board.
In this listing, kangxinuo biological plans to raise 1 billion yuan, of which, 550 million yuan will be used to invest in the second phase construction of its production base, 150 million yuan will be used for vaccine research and development, 50 million yuan will be used for vaccine traceability, cold chain logistics system and information system construction, and the remaining 250 million yuan will be used to supplement the working capital.
According to previous reports, the industrialization base of kangxinuo biologicals new crown vaccine is under construction at this stage, and the future production capacity is expected to be no less than 200 million doses. The fund-raising of the A-share Sci-tech Innovation Board will give strong support to the development of the vaccine.
The number of shares issued by the company this time is 24.8 million, accounting for 10.02% of the total share capital of the company after the issuance; the original shareholders of this issuance do not conduct public offering of shares, and the subscription scale of the special asset management plan of the issuers core employees participating in the strategic placement is not more than 59.24 million yuan.
The new crown vaccine has passed the second phase clinical trial
It is currently used in the military
Since then, there has been good news. Novel coronavirus vaccine (adenovirus vector) was approved by Conchino biological company (-B, 06185.HK, 06185.HK) announcement in early June 29th.
The novel coronavirus vaccine (Ad5-nCoV), jointly developed by the company and the Institute of Biomedical Engineering, Academy of Military Medical Sciences, was approved by the Health Bureau of the Logistics Department of the Central Military Commission (hereinafter referred to as the post military protection department) in June 25, 2020, and the validity period is one year, the announcement said.
According to the relevant provisions of the measures of the peoples Liberation Army for the implementation of the drug administration law of the peoples Republic of China, Ad5 ncov is only for internal use in the army at this stage, and it is not allowed to expand the scope of vaccination without the approval of the Military Commissions rear security department.
At the same time, we can not guarantee that we will be able to successfully commercialize Ad5 ncov.
Affected by this news, kangxinuo biological-b has been in high shock sorting since July.
The vaccine of Sinopharm group was launched at the end of the year
A-share vaccine concept stocks rose one after another
The commercialization of the vaccine developed by Kangxi Nuo biological Co., Ltd. is still to be determined, but the vaccine concept unit of A-share is on the rise.
On the evening of July 22, Liu Jingzhen, chairman of Sinopharm group, said in an interview with CCTV that Sinopharm group had been approved to start the phase III international clinical trial at the end of June and may be put on the market by the end of the year.
Liu Jingzhen said that the new crown vaccine was developed by the Beijing Institute of biological products under the State Pharmaceutical Group and the Wuhan Institute of biological products, which should be said to have been successful. On March 30, I already had a pre injection, which is equivalent to testing the medicine with my own body. On April 12, the vaccine entered the first and second phase clinical trials in China, and the effect was very ideal. There was no serious side effect. The effectiveness was 100%. At the end of June, we were approved to start the phase III international clinical trial.
At the same time, two institutes of sinopharma group have built P3 level production facilities at the same time, which can ensure the large-scale production of vaccine in the next step. According to the relevant regulations, it must go through the clinical phase I, II and III trials. At present, we have entered the final stage - phase III clinical trial. We can complete the clinical trial in about three months and enter the final approval stage. We should be able to go on the market before the end of the year.
Affected by this news, the temple of heaven biology of sinopharma group, China biology, was also trading on the 23rd. Affected by the market, as of press, the temple of heaven biological rose 6.75%.
In addition, there are Beirui fund, Liaoning Chengda and other biological vaccine concept stocks, fearing the deep adjustment of the market, continue to rise.
Source: Yang Qian, editor in charge of China fund daily_ NF4425